Texas A&M University
Latest From Texas A&M University
The founders of Rescue Therapeutics Inc. believe they have created a compound that can boost the power of widely used generic cancer drugs, including doxorubicin, without exposing a patient to any additional toxicity. Although RTI’s work with the compound was initially geared to testing it against non-Hodgkin's lymphoma, the start-up is taking it forward as a potential second-line treatment for ovarian cancer.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.